For PAH Treatment, Mylan Launches Tadalafil Tablets, 1st Generic...
WEBAug 22, 2018 — Mylan Announces U.S. Launch of 20 mg Tadalafil Tablets, 1st Generic of Adcirca for PAH Treatment. by Iqra Mumal, MSc August 22, 2018. Mylan recently introduced a formulation of 20 mg tadalafil tablets, the first generic version of Eli Lilly ‘s Adcirca, in the United States for patients with pulmonary arterial hypertension (PAH).
Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
WEBby Iqra Mumal, MSc July 8, 2019. An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.
Tyvaso Becomes 1st PH-ILD Treatment Approved in US
WEBApr 1, 2021 — The U.S. Food and Drug Administration (FDA) approved Tyvaso, developed by United Therapeutics, to improve exercise ability in PH-ILD patients, the company said. “The regulatory approval of Tyvaso, an inhaled treatment, is exciting news both for patients with PH-ILD and the physicians who treat adults living with this serious, life-threatening disease” — for which there were no approved ...
Revatio (Sildenafil Citrate) for Pulmonary Hypertension
WEBRevatio (sildenafil) is a U.S. Food and Drug Administration-approved medication used to slow the progression of pulmonary arterial hypertension (PAH) and improve the ability to exercise. It is marketed by Pfizer.. How Revatio works. PAH symptoms are caused by narrowing of the pulmonary arteries (blood vessels connecting the heart and lungs). This restricts the blood flow, causing strain to the ...
INOPulse Device Leads to Clinically Meaningful Improvement in...
WEBby Iqra Mumal, MSc November 18, 2019. Use of Bellerophon Therapeutics’s INOpulse device led to clinically meaningful improvements in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to initial data from an ongoing clinical study. PH-ILD is associated with constriction or narrowing of pulmonary ...
Updated PAH Treatment Guidelines Released by CHEST
WEBFeb 13, 2019 — The free guide, titled “ Therapy for Pulmonary Arterial Hypertension in Adults 2018: Update of the CHEST Guideline and Expert Panel Report, ” was published in the journal Chest. PAH is a progressive lung disorder caused by increased pressure in the lung blood vessels. Available treatment options for the disease help alleviate the pressure, reduce inflammation, and improve blood flow.
Six-minute Walk Test Still Key in Predicting Long-Term PAH …
WEBMay 4, 2018 — The study, “ Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial, ” was published in the journal PLOS ONE. It investigated the association between six-minute walk distance and long-term outcomes in patients with PAH.. The study was based on data collected from the Phase 3 trial ...
FDA approves sotatercept, now Winrevair, to treat PAH in adults
WEBMar 27, 2024 — The now-approved treatment is expected to be available for dispensing by select U.S. specialty pharmacies by the end of April, according to Merck, which has owned the rights to the biologic therapy since acquiring prior developer Acceleron Pharma in 2021. Winrevair specifically is intended to enhance exercise capacity, improve World Health Organization (WHO) functional class, and reduce the ...
Pulmonary Venous Hypertension (PVH)
WEBJun 29, 2021 — The symptoms of PVH are similar to those of other types of PH. Patients may experience shortness of breath, tiredness, chest pain, and fainting during normal activity, but are comfortable at rest. Swelling of the legs and ankles also may occur. Patients with PVH often have sleep apnea, which is repeated stops and starts of …
Gilead’s Letairis with Tadalafil Approved by FDA for Pulmonary...
WEBOct 5, 2015 — Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Letairis ® (ambrisentan) with tadalafil for pulmonary arterial hypertension (PAH) to diminish disease progression risk and hospitalization and to improve the ability to exercise — a decision that directly follows recent study results indicating the efficacy of the combination therapy in PAH patients.
Skip to content